Assessing the long-term safety of biologics for psoriasis
Biologic therapies are a relatively new treatment option for patients with psoriasis. However, their long-term safety has not been assessed yet. The British Association of Dermatologists (BAD) has set up a register – the British Association of Dermatologists’ Biologics Intervention Register (BADBIR) – to investigate the long-term outcome of psoriasis patients treated with biologic agents, and thus better assess the risks associated with such treatments. This article explains how this new register works and why it was established.
Dermatology in practice 2008; 16(1): 8–11
To continue reading this article, please sign in or register.